精神分裂症药物治疗进展

Progress of pharmacotherapy for schizophrenia

第二代抗精神病药物副反应较少，可接受度较高，但其对精神分裂症的疗效仍与第一代抗精神病药物相当，因此，临床上迫切需要能够更好地治疗精神分裂症患者的药物。未来新型抗精神病药物的开发，主要应立足于解决阴性症状、认知缺陷和瓦解症状，提高药物的安全性。

Adverse reactions of second-generation antipsychotics （SGA） are less, but their effieacies equivalent to first-generation antipsychotics （FGA）, for this reason drugs treating schizophrenia preferably are needed urgently at present. The future development of new antipsyehotic drugs should aim directly at treating negative symptoms, cognitive impairment and disintegration symptoms and im- proving drug＇s safety.